EVERETT, Wash.--(BUSINESS WIRE)--SNBL USA, the experts in primate research, is pleased to announce the appointment of Alan Breau, Ph.D., as director of laboratory services. A 20-year veteran of the industry, Breau will provide scientific and innovative oversight of SNBL USA’s scientific research for its clients in the areas of flow cytometry, virology, formulations and analytical chemistry as well as other preclinical services.
Prior to joining SNBL USA, Breau was the chief operating officer and co-founder of CRO Biologics Development Services and vice president of analytical services at MPI Research. He has more than 20 years of project team experience with early discovery and full development projects. Throughout his extensive career, he has held various positions managing bioanalytical, analytical and immunology departments that provided analytical services for clients developing small molecules, large molecules and hybrid molecules such as antibody drug conjugates.
"Alan has the perfect background and experience to direct SNBL USA’s laboratory services team,” said Dr. Thomas Beck, SNBL USA president and chief operating officer. "He will drive the vision and strategy for our laboratory services group and streamline efficiencies. With his scientific, industry and corporate experiences, Alan will provide an important new dimension as SNBL USA expands our support to the scientific priorities of our clients while meeting their laboratory services’ needs."
For additional information regarding SNBL USA services and capabilities, contact SNBL USA at 425.322.1950 or info@snblusa.com.
About SNBL USA, Ltd.
Headquartered in Everett, Wash., SNBL
USA, Ltd. offers a unique range of safety assessment services to
fulfill its commitment to help free patients from suffering. Managed and
operated by a team world renowned for its wide-ranging nonhuman primate
(NHP) experience and expertise, SNBL offers programs ranging from
regulatory toxicology to customized study designs. SNBL’s specialized
capabilities include safety assessment of biologics, reproductive
toxicology, efficacy models (ARS, HIV), cardiovascular, respiratory and
CNS pharmacology, immunotoxicology and carcinogenicity.
